Dupilumabe como alternativa de tratamento na dermatite atópica moderada a grave: estudo de caso

Abstract

This is a 28-year-old-individual case with moderate to severe atopic dermatitis (AD) who responded well to Dupilumab. AD is a chronic, itchy, inflammatory skin disease that occurs most often in children, but it also affects adults. The participant had already used two agents for the treatment of atopic dermatitis, without obtaining adequate control of the disease. He made use of all control measures for severe cases of the disease: careful bathing, environmental control, potent topical corticosteroids and emollients, even so he had constant itching and skin lesions and poor quality of life. Patients with severe refractory AD who have not responded to standard first-line therapies, and have generalized disease that limits daily activities, psychosocial functioning and/or sleep, with considerable negative impact on quality of life. For treatment, topical, phototherapy or systemic therapies are available. Dupilumab is a relatively new drug for the treatment of atopic dermatitis, approved in 2018 for this condition. It is a monoclonal antibody. The evolution of the case was observed through photographic and SCORAD comparisons before and after sixteen applications of Dupilumab.